NEW YORK (GenomeWeb) – Veracyte said on Thursday it has amended a loan agreement with Silicon Valley Bank originally forged in June 2013.

Under the terms of the amendment, Veracyte can borrow up to $15 million in three tranches, each tranche not exceeding $5 million. The company borrowed $5 million from the first tranche this week to repay in full the initial $5 million loan drawn in June 2013, the San Francisco-based developer of gene expression-based diagnostic tests said in a document filed with the US Securities and Exchange Commission. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.